Posted by Mike > 2020-12-05 14:03 | Report Abuse

i thought he dumped all 150 million shares he owned

Posted by y220555 > 2020-12-05 14:06 | Report Abuse

This wu wai kong culprit exercise of share option scheme 40,000,000 shares on 18/11/2020 at 0.065 & 0.07, announcement date 24/11/2020

Posted by huatkopi88 > 2020-12-05 14:46 | Report Abuse

Oops 150m a lot, not 1.5m.

Posted by mikho69 > 2020-12-05 14:52 | Report Abuse

it seems to me changing hands..if want to cabut why dont goreng till higher price ie pfizer directors..my 2 cents lah

Posted by mikho69 > 2020-12-05 14:55 | Report Abuse

sold 0.17 and 0.175..i dont get it..just something to ponder..wu could hv sold much higher

Posted by huatkopi88 > 2020-12-05 15:01 | Report Abuse

We shall know next week. If share drop below 0.17 then he got insider info. If share rise 0.18 and above, then I don't know what to say

Posted by rockrziq > 2020-12-05 15:03 | Report Abuse

Yong Tai is obviously a goreng counter. No confirmation yet from the vaccine manufacturer the share price already goes up ? That's the easiest way to detect goreng counter.

Posted by rockrziq > 2020-12-05 15:05 | Report Abuse

Kanger is completely in normal phenomena. Many people are watching Kanger, waitting for MOH clinical test by the end of this month or next year. Why the big boys would enter if no confirmation yet ? Better they go play (low volume + news) to goreng.

Posted by huatkopi88 > 2020-12-05 15:05 | Report Abuse

I don't mind Kanger goreng like YongTai as long we make money. If no one goreng, will be dormant no volume.

Posted by rockrziq > 2020-12-05 15:05 | Report Abuse

Right now its in accumulation phase, thats a completely normal for a HEALTHY stock to rise.

Posted by rockrziq > 2020-12-05 15:07 | Report Abuse

You know the consequences of goreng counter right ? It's not good for investors. People pump and dump will ruin the counter and track record. Just look at Vivocom, AT, MMAG what happened. If you want to make money fast, why don't you go to goreng counter ?

Posted by rockrziq > 2020-12-05 15:12 | Report Abuse

Let me give you a tips if you want fast money. Read the sentiment, low volumes counter, sideways chart, news (MoU is enough), penny stock. Sure goreng one. Beware of the risk though. Dont chase price. If you tertinggal bas just let it go find another one.

Posted by NPRA1985 > 2020-12-05 15:37 | Report Abuse

@UlarSawa That is a different vaccine from China la, not Sinopharm vaccine...Of course that vaccine will need to be approved in the home country (after phase 3 trial has been completed) before it can be considered for approval by MOH.

"Health director-general Datuk Dr Noor Hisham Abdullah said the trial would be a Phase 3 clinical trial on a vaccine that has been developed by the Institute of Medical Biology Chinese Academy of Medical Sciences (IMBCAMS) in Beijing."

https://www.nst.com.my/news/nation/2020/12/646768/malaysias-first-covid-19-vaccine-trial-involve-3000-people

Posted by UlarSawa > 2020-12-05 15:53 | Report Abuse

MOH staff. so kanger vaccine not in msia trial. then how to use it. Then need WHO approval right. whem kanger can import china vaccine into msia for sales? correct?

Posted by NPRA1985 > 2020-12-05 16:03 | Report Abuse

@UlarSawa It is not a requirement to conduct local clinical trials in Malaysia in order to approve the vaccine. The same goes for Pfizer vaccine. No local clinical trials will be conducted for Pfizer vaccine. Application for WHO approval of Sinopharm vaccine can only happen after the vaccine has first been approved by China's National Medical Products Administration.

Posted by purple_rain > 2020-12-05 16:07 | Report Abuse

@ularsawa, Sinopharm had done Phase 3 trial and now in final stage of approval. Whereas, IMBCAMS had done Phase 2 and now going into Phase 3.
Sinopharm is ahead of IMBCAMS in timeline. However both are using same type of Vaccines based on Inactivated SARS-CoV-2

https://en.wikipedia.org/wiki/COVID-19_vaccine#Clinical_trials_started_in_2020

Posted by UlarSawa > 2020-12-05 16:10 | Report Abuse

kanger vaccine tested in Msia? If MOH not tested how to get MOH approval to use in msia if WHO not approve kanger vaccine yet. Msia need to test kanger vaccine whether suitable for local communities use. correct?

Posted by night_shadow > 2020-12-05 16:16 | Report Abuse

@UlarSawa No MOH wont do their own test or trial, they’ll just study the data & research done by the fellow scientists, that’s how it has always been for all the previous vaccine administered by MOH.

Posted by eyeHunter > 2020-12-05 16:17 | Report Abuse

LOOK HERE
Bintai Kinden has to PAY Generex US$2.63 million (RM10.93 million) for the pre-commercialisation stage and US$10 million for the commercialisation stage, in relation to the intellectual property, commercialisation, distribution, licensing and other rights granted. It will use internal funds and bank borrowings to do so. “The licensing cost will be shared with our strategic partners in the other markets,” says Ong.
Has Kanger paid anything yet?

Posted by UlarSawa > 2020-12-05 16:17 | Report Abuse

moderna applying to get approval in Spore HSA. they do it online with real time data release to Spore Regulator to speed up the approval. China vaccine too secretive become slow like tortoise. how to become the earlybird ? correct?

Posted by Noobie123 > 2020-12-05 16:18 | Report Abuse

AntiVax spotted

Posted by UlarSawa > 2020-12-05 16:20 |

Post removed.Why?

Posted by purple_rain > 2020-12-05 16:27 | Report Abuse

@eyehunter, The more important question is, is Bintai betting on a wrong horse (Generex) that is at Pre-clinical Trial (testing on animal).
So many horses are about to cross the finish line. Is Bintai going to be too late for the party?

Posted by eyeHunter > 2020-12-05 16:34 | Report Abuse

@purwple_rain they said they are expanding to health services long term.

Posted by eyeHunter > 2020-12-05 16:38 | Report Abuse

@purwple_rain that's a good question.

Posted by purple_rain > 2020-12-05 16:40 | Report Abuse

Which is the closest to regulatory approval?

Both Sinopharm and Sinovac seem to be running neck-and-neck.

Sinopharm subsidiary CNBG submitted an application to China’s Food and Drug Administration for regulatory approval this month, according to Chinese media reports last week. It’s unclear which of its two vaccine candidates the application was for, or if it applied for both.

Meanwhile, Brazilian regulators have said they expect to see the vaccine that has been tested there—Sinovac’s CoronaVac—get regulatory approval in China this month.

The “major announcement” teased by Wang, the deputy head of China’s task force on vaccine development, on Dec. 4, could refer to upcoming regulatory approval for one or more vaccines.

https://qz.com/1940097/what-we-know-about-chinas-covid-19-vaccines/

Posted by rockrziq > 2020-12-05 16:45 | Report Abuse

Bintai management looks good but not Generex. It's just too far behind.

Posted by eyeHunter > 2020-12-05 16:50 | Report Abuse

The matter of fact is not about the vaccines, it's about Kanger management!! Only they know what's going on inside.

Posted by eyeHunter > 2020-12-05 16:51 | Report Abuse

We shall wait for their move.ok

Posted by rockrziq > 2020-12-05 17:09 | Report Abuse

Yeap, in our case Sinopharm looks very promising. No worry about that. It's just Kanger management's very secretive, they should announce what are they going to do with the PP money in detail and how are they going to get the vaccines. The roadmap.

Posted by rockrziq > 2020-12-05 17:15 | Report Abuse

But they got the letter from gov, I believe gov did check their plans and gives a green light.

Posted by rockrziq > 2020-12-05 17:25 | Report Abuse

That's the problem. How to convince investors like that.

Posted by NPRA1985 > 2020-12-05 17:41 | Report Abuse

@UlarSawa The only reason Pfizer and Moderna vaccine is faster is due to the huge number of Covid cases in USA. Hence they are able to collect and analyse the data faster.

Posted by NPRA1985 > 2020-12-05 17:46 | Report Abuse

Kanger should announce the investor for the private placement. Only question is when....

Posted by NPRA1985 > 2020-12-05 17:47 | Report Abuse

lol what is @eyeHunter still doing here... i thought he is not interested in Kanger...weirdo...

Posted by eyeHunter > 2020-12-05 17:48 | Report Abuse

Kiv

Posted by huatkopi88 > 2020-12-05 18:48 | Report Abuse

https://www.washingtonpost.com/world/asia_pacific/coronavirus-vaccine-china-bribery-sinovac/2020/12/04/7c09ae68-28c6-11eb-9c21-3cc501d0981f_story.html?outputType=amp
Sinopharm looking good as Sinovac get entangled in bribery claim

Posted by NPRA1985 > 2020-12-05 22:13 | Report Abuse

How China’s COVID-19 could fill the gaps left by Pfizer, Moderna, AstraZeneca

But amid the optimism, experts have raised some concerns about the accessibility of Pfizer and Moderna's candidates, which require costly cold-chain distribution mechanisms, and about the quality of the data provided by British vaccine maker AstraZeneca.

At the same time, China's two leading vaccine makers—the private Sinovac and state-owned Sinopharm—appear close to rolling out their vaccines in coming weeks with candidates that don't require expensive cold chain networks.

Western vaccine makers appear to have taken the lead in the global race to produce a vaccine, but Chinese vaccine makers may help fill in the gaps they leave behind.

Still, Pfizer and Moderna’s vaccines are based on newly-developed mRNA technology that requires the candidates to be kept at sub-zero temperatures during shipments. Such temperature restrictions will make it difficult for lower- and middle-income countries to access the vaccines because they will need cold-storage infrastructure to distribute the doses.

In Indonesia, for example, the country's state-owned vaccine manufacturer Bio Farma said that Indonesia, the world's fourth-most populous nation, effectively cannot purchase Pfizer's vaccine given the logistical challenges in distributing it.

"Indonesia does not have such [cold-chain] capabilities, and it is hazardous if this vaccine is not stored at the proper temperature," Honesti Basyir, head Bio Farma, told Indonesian news outlet the Jakarta Globe on Nov. 22. In India, the country's 28,000-unit cold chain network used for distributing vaccines only handles vaccines between 2 and 8 degrees Celsius.

But in the days after AstraZeneca’s announcement, experts raised questions over the "transparency and rigor" of AstraZeneca’s data. Scientists questioned why the most effective results emerged from an apparent dosing error, and how datasets from multiple countries were combined and tabulated into the final results. In response, a spokesperson for AstraZeneca said its trials were conducted to the "highest standards." Still, amid the questions over its trial data, AstraZeneca CEO Pascal Soriot pledged that the company would conduct an additional study to validate its results

AstraZeneca’s woes and the potential distribution limitations of the Pfizer and Moderna vaccines have left a hole in the global supply that may be filled by Chinese vaccine makers, says Yanzhong Huang, senior fellow for global health at the Council on Foreign Relations.

Sinovac and Sinopharm, China’s two leading vaccine makers, are currently testing three vaccine candidates in phase III trials with candidates that could be distributed without cold storage chains. Sinovac's candidate, called CoronaVac, uses inactivated forms of COVID-19 to induce immune responses. Sinopharm's two unnamed candidates are both based on similar technology.

Beijing "absolutely" sees these Chinese-made vaccines as a potential substitution for AstraZeneca's candidate, says Huang. In state media outlets, Beijing is presenting Sinovac and Sinopharm's candidates as "particularly attractive to lower and middle income countries, especially the ones who cannot afford or don't have the capacity to sustain cold chain to distribute vaccines," Huang says.

Because they rely on inactivated forms of the virus, Sinovac's and Sinopharm's candidates are more stable in comparison to vaccines based on mRNA technology, meaning they don't need to be kept quite as cold. Similar to AstraZeneca, Sinovac says its vaccine can be stored and shipped at temperatures ranging from 2 to 8 degrees Celsius. Chinese state media reports that Sinopharm's candidates can likely be stored at a similar 2 to 8 degree Celsius range. Sinopharm declined Fortune's request for confirmation.

Admiral Craig Fuller, the U.S.'s top commander in Central and South America, told reporters this week that while the U.S. is focused "on taking care of the U.S. first," China is poised to deploy its vaccines around the world.

Still, Sinopharm may have a built-in edge given its established distribution networks within China and the fact that it is testing its vaccine in a broader array of countries than other Chinese vaccine makers.

"[Sinopharm's] large scale rollout [via China's emergency use program] also means that there is already a large distribution system, which has already been stress-tested," says Nicholas Thomas, a vaccine expert and health governance professor at the City University of Hong Kong. "This is a major advantage in the future distribution." Sinopharm is also already distributing vaccines to the United Arab Emirates via that country's emergency use program, and is testing, or plans to conduct trials, in at least ten countries including Egypt, Jordan, and Argentina.

Posted by NPRA1985 > 2020-12-05 22:14 | Report Abuse

https://fortune.com/2020/12/05/china-covid-19-vaccines-approval-sinovac-sinopharm/

Posted by MadCow75 > 2020-12-05 23:50 | Report Abuse

slow and steady... but too slow...

Posted by freddiehero > 2020-12-05 23:51 | Report Abuse

right, believe on urself, u can do it...

Posted by NPRA1985 > 2020-12-06 00:59 | Report Abuse

All the other vaccine counters already goreng, so it is only a matter of time for Kanger....

Posted by NPRA1985 > 2020-12-06 02:33 | Report Abuse

EU criticises ‘hasty’ UK approval of COVID-19 vaccine
European Medicines Agency says its approval process is more appropriate, as German politician calls UK move ‘problematic’.

European regulators have issued caution over the United Kingdom’s move to approve Pfizer-BioNTech’s COVID-19 vaccine for widespread use, saying their longer approval process was safer.

In an unusually blunt statement, the European Medicines Agency (EMA), which is in charge of approving COVID-19 vaccines for the EU, said its longer approval procedure was more appropriate as it was based on more evidence and required more checks than the emergency procedure chosen by the UK.

A spokesman for the European Commission, the EU executive, said the EMA’s procedure was “the most effective regulatory mechanism to grant all EU citizens’ access to a safe and effective vaccine,” as it was based on more evidence.

The EMA’s comments came hours after the UK became the first country in the world to approve the drug developed by Pfizer and BioNTech for use.

Peter Liese, an EU legislator and member of German Chancellor Angela Merkel’s Christian Democratic Union party, struck a firmer tone, saying he considered the MHRA’s approval to be “problematic”.

“I recommend that EU member states do not repeat the process in the same way,” he said.

“A few weeks of thorough examination by the European Medicines Agency (EMA) is better than a hasty emergency marketing authorisation of a vaccine.”

https://www.aljazeera.com/news/2020/12/2/eu-criticises-hasty-uk-approval-of-covid-19-vaccine

Posted by NPRA1985 > 2020-12-06 02:52 | Report Abuse

Pfizer shares fall on report company cut its Covid vaccine rollout target

Pfizer shares fell Thursday after a report said the U.S. drugmaker expects to ship half of the Covid-19 vaccines it originally planned for this year due to supply-chain problems.

The company has repeatedly said publicly that it planned to ship 50 million vaccine doses this year and up to 1.3 billion doses by the end of 2021.

The Wall Street Journal, citing a person directly involved in the development, said some early batches of the raw materials needed for the vaccine failed to meet standards. Pfizer now plans to ship 50 million vaccines by the end of the year, down from the original 100 million it had hoped to send out, according to the Journal.

https://www.cnbc.com/2020/12/03/pfizer-shares-fall-on-report-company-cut-its-covid-vaccine-rollout-target.html
-----------------------------

Pfizer Scaled Back 2020 COVID-19 Vaccine Production Targets From 100 Million to 50 Million Doses

Pfizer scaled back its Covid-19 production targets earlier this year after the drugmaker ran into difficulties securing all the materials it needs to produce the shots at a large scale.

In news releases through September, Pfizer had said that it aimed to manufacture up to 100 million vaccine doses this year. But in several releases in November, the company cut that to an estimate of up to 50 million doses. Pfizer is developing its vaccine with Germany-based BioNTech SE.

A Pfizer spokeswoman said in a statement Thursday that multiple factors slowed the company down, including the time it took to source large quantities of the raw materials needed to produce the shots. But the company said it has finished bringing its manufacturing up to scale and it is now producing vaccines at a rapid pace.

https://time.com/5917847/pfizer-cut-covid-19-vaccine-targets/

Posted by Orlando > 2020-12-06 08:22 | Report Abuse

According to mkt rumor Nur n proxies hv bin collecting KANGER shares n d most recent was 150m from Wu

Collected n ready

Posted by Orlando > 2020-12-06 08:24 | Report Abuse

Change in boardroom DONE

Change in shareholders DONE

KANGER gonna start moving north in line wit d progress of SINOPHAM vaccine

Posted by Noobie123 > 2020-12-06 09:16 | Report Abuse

Kementerian Kesihatan Malaysia (KKM) ingin memaklumkan bahawa sehingga kini, Bahagian Regulatori Farmasi Negara (NPRA) masih belum menerima sebarang dokumen daripada syarikat Pfizer untuk penilaian pendaftaran dan pengujian produk vaksin COVID-19 sekaligus tidak mempunyai sebarang maklumat berkaitan isu masalah pembekalan dos vaksin tersebut sebagaimana yang dilaporkan. Walau bagaimanapun, KKM akan sentiasa memantau perkembangan produk vaksin COVID-19 oleh Pfizer dan mendapatkan maklumat lanjut mengenai perkara ini.

Adalah menjadi tanggungjawab NPRA, KKM untuk memastikan sebelum sesuatu produk didaftarkan untuk dipasarkan di Malaysia, ia perlu terlebih dahulu melalui proses penilaian dan pengujian berasaskan prinsip-prinsip kualiti, keselamatan dan juga keberkesanan. NPRA juga memastikan kualiti, keselamatan dan keberkesanan vaksin serta ubat-ubatan yang berdaftar sentiasa terjamin melalui program pemantauan mutu produk berdaftar dan farmakovigilans. Pihak KKM akan memaklumkan perkembangan terkini kepada orang ramai dari semasa ke semasa.

TAN SRI DATO’ SERI DR. NOOR HISHAM BIN ABDULLAH

KETUA PENGARAH KESIHATAN MALAYSIA

6 DISEMBER 2020

Posted by Legend > 2020-12-06 09:20 | Report Abuse

Slow..

Posted by Orlando > 2020-12-06 09:20 | Report Abuse

After Malaysia signed d agreement thn only Prizer give tis kind shit

Posted by kingrator > 2020-12-06 09:39 | Report Abuse

@orlando, who is Nur? where u get the rumors?